Copy Link Print Information

Bevacizumab

(Synonyms: Anti-Human VEGF, Humanized Antibody)
66 Cited Publications
Revisión del cliente

Based on 66 publication(s) in Google Scholar

Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 98.30%
  • No. CAS: 216974-75-3
  • Peso molecular:146.56 kDa
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Bevacizumab Chemical Structure
    Bevacizumab Chemical Structure
No. CAS: 216974-75-3
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Bevacizumab:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Bevacizumab

More
Customer Validation & Images
IHCWBIn Vivo Efficacy StudyCell Migration/Invasion AssayIFOthersFlow Cytometry
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • IHC
  • In Vivo Efficacy Study
  • Flow Cytometry
  • WB
  • IF
  • Cell Migration/Invasion Assay
  • Others

Ver todos los productos específicos de isoformas VEGFR

More

Keywords

MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Flow cytometric analysis of 1X106 Hela cells with Bevacizumab (HY-P9906, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC50 for this effect is 5.34 ng/mL.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 24;10(1):417. [Abstract]

    Customer Validation
     Treatment of PC9-BM LCN2-high BM-bearing mice with SH4-54 (10 mg/kg, intraperitoneally, twice per week), Bevacizumab (10mg/kg, intraperitoneally, twice per week), or a combination of both significantly suppressed tumor progression and prolonged overall survival.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: J Clin Oncol. 2025 Mar;43(7):840-851. [Abstract]

    Customer Validation
     Tumor-bearing mice were treated with vehicle, Onvansertib, and/or Bevacizumab (intraperitoneally, 5 mg/kg for SW620 and HCT116, 1 mg/kg for LoVo, twice a week) for 30-33 days.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):619-638. [Abstract]

    Customer Validation
     VEGFA IHC staining in control and ATL-I (80 μM or 160 μM)-treated Matrigel plugs. Quantification of vegfa-positive cells. Scale bar: 100 μm. In the present set of experiments, Bevacizumab (50 ng/ml) was used as the positive control.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Atezolizumab (4 mg/kg; i.v.) + Bevacizumab (1 mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Collected tumor tissues of mice at the end of treatment in different groups.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Atezolizumab (4mg/kg; i.v.) + Bevacizumab (1mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45+ cells), anti-CD68/CD80-stained macrophages (gated on CD45+ cells),anti-HLA-DR/CD11c-stained DCs (gated on CD45+ Lin-1- T cells), and anti-CD3/CD8-stained T cells (gated on CD45+ cells) in tumor tissues after different treatments (n = 5 independent mice).

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]

    Customer Validation
     Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) significantly reversed the upregulatory effect of TQHXD and HXHY on VEGFA protein in MCAO rats.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]

    Customer Validation
     Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) effectively antagonized the inherent pro-angiogenic effects of TQHXD and HXHY in MCAO rats.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]

    Customer Validation
     Transwell assays showing that Bevacizumab (200 ng/mL, 12 h) failed to inhibit the migration of HUVECs treated with recombinant PTN protein. Unpaired t test; **, P < 0.01; ****, P <0.0001.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]

    Customer Validation
     Tube formation assays showed that Bevacizumab (200 ng/mL) failed to inhibit the tube formation of HUVECs induced by recombinant PTN protein.Unpaired t test; ***, P <0.001; ****, P <0.0001.

  • Bevacizumab Chemical Structure
    1/16
  • Bevacizumab
  • Flow cytometric analysis of 1X106 Hela cells with Bevacizumab (HY-P9906, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC50 for this effect is 5.34 ng/mL.